TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06693479

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shoulder watch load (SWL) feedback
Description: During week 2 and 3 after randomisation, the experimental group will undergo the intervention using the SWL, designed to monitor workers' physical work demands. During this time, the SWL will provide real-time feedback based on parameters set via Ergowatchapp. Two workplace visits by a physiotherapist will be conducted to establish and adjust the feedback thresholds: once in week 2 and again in week 3. The goal is to demonstrate that the feedback promotes changes in strategies used by workers to manage their shoulder pain. Only the experimental group will receive feedback from the SWL during the study period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Participants will receive an education intervention delivered by a physiotherapist. This intervention will take place at the participants' workplace at the end of the 2nd week post-randomization. The session will last 30 to 45 minutes, and involve personalized, patient-centered education on their condition. The physiotherapist will use open-ended questions to encourage participants to express their goals and address specific concerns related to their shoulder condition. Given the expected diversity in physical constraints (manual vs. non-manual workers) and individual challenges, the session will be tailored to each worker needs. At the end of the session, workers will receive a booklet summarizing key points, including: understanding shoulder anatomy, function and pain, managing shoulder pain, enhancing movement variability, adjusting work environment, and considering factors such as sleep, stress, coping mechanisms, and psychological factors on pain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Participants will receive an education intervention delivered by a physiotherapist. This intervention will take place at the participants' workplace at the end of the 2nd week post-randomization. The session will last 30 to 45 minutes, and involve personalized, patient-centered education on their condition. The physiotherapist will use open-ended questions to encourage participants to express their goals and address specific concerns related to their shoulder condition. Given the expected diversity in physical constraints (manual vs. non-manual workers) and individual challenges, the session will be tailored to each worker needs. At the end of the session, workers will receive a booklet summarizing key points, including: understanding shoulder anatomy, function and pain, managing shoulder pain, enhancing movement variability, adjusting work environment, and considering factors such as sleep, stress, coping mechanisms, and psychological factors on pain.
Study: NCT04473937

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy at pre-determined dose and schedule
Study: NCT06692452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: EZH2 inhibitor, 200 mg tablet, taken orally per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: EZH2 inhibitor, 200 mg tablet, taken orally per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Anthracycline antibiotic, 10, 20, 50, 100, and 200 mg vials, via intravenous (into the vein) infusion per institutional standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Anthracycline antibiotic, 10, 20, 50, 100, and 200 mg vials, via intravenous (into the vein) infusion per institutional standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vinca Alkaloid, 1, 2, and 5mL vials, via intravenous (into the vein) infusion per institutional standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vinca Alkaloid, 1, 2, and 5mL vials, via intravenous (into the vein) infusion per institutional standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Corticosteroid, 1, 2.5, 5, 10, 20, 25, and 50 mg tablets, taken orally per institutional standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Corticosteroid, 1, 2.5, 5, 10, 20, 25, and 50 mg tablets, taken orally per institutional standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: Alkylating agent, 100mg, 200 mg, and 500mg vials, and 1 and 2 gram vials, via intravenous (into the vein) infusion per institutional standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: Alkylating agent, 100mg, 200 mg, and 500mg vials, and 1 and 2 gram vials, via intravenous (into the vein) infusion per institutional standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Alkylating agent, 100 mg single dose vials, via intravenous (into the vein) infusion per institutional standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Topoisomerase II inhibitor, 100mg single dose vial, via intravenous (into the vein) infusion per institutional standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Antineoplastic, 20mg single dose vial, via intravenous, intrathecal, or subcutaneous injection per institutional standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Alkylating agent, 90 mg multi-dose vial, via parenteral infusion per institutional standard of care.
Study: NCT06732037

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy program
Description: The conventional physical therapy program will be received for 8 weeks by the two groups. It includes the application of moist heat using a hot pack for ten minutes, followed by continuous ultrasound therapy operated at a frequency of 1 MHz and an intensity of 1.5 W/cm² for five minutes. Transcutaneous Electrical Nerve Stimulation (TENS) will also be utilized, with its development and application based on the Gate Control Theory. TENS will be applied for twenty minutes, with electrodes positioned on either side of the neck at the level of pain, using a pulse rate ranging from 2 to 50 Hz.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy program
Description: The conventional physical therapy program will be received for 8 weeks by the two groups. It includes the application of moist heat using a hot pack for ten minutes, followed by continuous ultrasound therapy operated at a frequency of 1 MHz and an intensity of 1.5 W/cm² for five minutes. Transcutaneous Electrical Nerve Stimulation (TENS) will also be utilized, with its development and application based on the Gate Control Theory. TENS will be applied for twenty minutes, with electrodes positioned on either side of the neck at the level of pain, using a pulse rate ranging from 2 to 50 Hz.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinetic control training
Description: The Kinetic Control Retraining Program will be received for 8 weeks by the experimental group. It focuses on addressing uncontrolled movement (UCM) and muscle synergy retraining. UCM retraining starts with patient education on movement deficiencies, their symptoms, and adherence to training. Movement coordination is retrained in test positions, progressing to challenging ones using feedback from mirrors, walls, or hands. Corrections focus on lower cervical flexion, upper cervical extension, mid-cervical translation/extension, side-bending, and rotation, emphasizing controlled dissociation in supported and unsupported postures. Muscle synergy retraining targets global stabilizers (e.g., deep neck flexors and extensors) and mobilizers (e.g., sternocleidomastoid and suboccipital muscles) to enhance coordination, stability, and motor control.
Study: NCT06746701

Intervention type: DRUG
Intervention: Peg-IFNα-2b combined with NA
Description: From baseline day 1, take NA orally once daily until the drug can be discontinued. Concurrently, combine with Peg-IFN α-2b 180μg, administered subcutaneously once a week for 48-96 weeks (if the surface antigen is not converted to negative at week 48, continue Peg-IFN α-2b treatment, but the course of treatment should not exceed 96 weeks). Discontinue Peg-IFN α-2b (while maintaining continuous oral administration of NA), and continue taking NA orally.

Intervention type: DRUG
Intervention: Nucleotide Analogues
Description: Starting from the first day of enrollment, take NA orally once a day.
Study: NCT06747234

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oat bran group
Description: Patients consume 28 grams of oat bran daily for two months in addition to their usual medical treatment.

Intervention type: OTHER
Group type: OTHER
Intervention: Control (Standard treatment)
Description: Patients receive standard medical treatment.
Study: NCT06747949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dazodalibep
Description: Dazodalibep will be given intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dazodalibep
Description: Dazodalibep will be given intravenously (IV).
Study: NCT05911009

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BC 007 or matching placebo
Description: Participants will be treated with two infusions of BC 007 or placebo two weeks apart, according to a double-blind design

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BC 007 or matching placebo
Description: Participants will be treated with two infusions of BC 007 or placebo two weeks apart, according to a double-blind design
Study: NCT04725188

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Vibostolimab coformuation
Description: Pembrolizumab 200 mg + vibostolimab 200 mg/20 mL vial IV infusion Q3W up to approximately 2 years.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Vibostolimab coformuation
Description: Pembrolizumab 200 mg + vibostolimab 200 mg/20 mL vial IV infusion Q3W up to approximately 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg\^m2 IV infusion Q3W until discontinuation due to progressive disease or unacceptable toxicity. Docetaxel will serve as part of an experimental treatment in Arm 1, and as an active comparator in Arm 3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 mg\^m2 IV infusion Q3W until discontinuation due to progressive disease or unacceptable toxicity. Docetaxel will serve as part of an experimental treatment in Arm 1, and as an active comparator in Arm 3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Normal saline IV infusion Q3W up to approximately 2 years
Study: NCT06325852

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DBS programing
Description: The physician will utilize the Boston Scientific Chronos Clinician Programmer (software) to make adjustments to the Deep Brain Stimulation (DBS) settings for the patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DBS programing
Description: The physician will utilize the Boston Scientific Chronos Clinician Programmer (software) to make adjustments to the Deep Brain Stimulation (DBS) settings for the patients.
Study: NCT06002477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecamylamine Challenge
Description: Mecamylamine 20 mg oral pill administered once

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator Challenge
Description: Matching placebo oral pill administered once
Study: NCT06402136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 83-0060
Description: Oral MPro inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 83-0060
Description: Oral MPro inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 83-0060
Description: Oral MPro inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 83-0060
Description: Oral MPro inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 83-0060
Description: Oral MPro inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 83-0060
Description: Oral MPro inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 83-0060
Description: Oral MPro inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 83-0060
Description: Oral MPro inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT05911009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BC 007 or matching placebo
Description: Participants will be treated with two infusions of BC 007 or placebo two weeks apart, according to a double-blind design

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BC 007 or matching placebo
Description: Participants will be treated with two infusions of BC 007 or placebo two weeks apart, according to a double-blind design
Study: NCT05411484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoDOX® Hydrogel
Description: NanoDOX® Hydrogel (Doxycycline Monohydrate USP) will be applied on the areas of the skin previously treated by the Co2 Ablative Fractional Laser and also on a small non treated area of the subject's skin
Study: NCT06343350

Intervention type: DEVICE
Intervention: OPTDR01 software application
Description: Retinal images will be sent to the OPTDR01 software application for mtmDR and vtDR detection
Study: NCT05411484

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 Ablative Fractional Laser
Description: CO2 Ablative Fractional Laser will be applied to healthy skin areas
Study: NCT06402136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT05012618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUNA18
Description: LUNA18 Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUNA18
Description: LUNA18 Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUNA18
Description: LUNA18 Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUNA18
Description: LUNA18 Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUNA18
Description: LUNA18 Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUNA18
Description: LUNA18 Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab as a IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab as a IV infusion
Study: NCT06644768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valemetostat tosylate
Description: Valemetostat will be administered orally once daily until RP2D of valemetostat is determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valemetostat tosylate
Description: Valemetostat will be administered orally once daily until RP2D of valemetostat is determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: One IV infusion Q3W on D1 of each 21-day cycle for a maximum of 35 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pembrolizumab
Description: One IV infusion Q3W on D1 of each 21-day cycle for a maximum of 35 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: One IV infusion Q3W on D1 of each 21-day cycle for a maximum of 35 cycles.
Study: NCT06641401

Intervention type: PROCEDURE
Intervention: Endoscopic Flexor Hallucis Longus transfer for Acute Achilles tendon rupture
Description: All patients have already undergone the same operation for the same disease. All data are to be collected retrospectively
Study: NCT06642844

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin, 25 Mg/mL Intravenous Solution
Description: Experimental group/ Patients randomized to the experimental group of the trial will receive bevacizumab as an IV infusion at a dose of 10 mg/kg, administered in 2 preparations of 5 mg/kg, every 2 weeks. Patients will receive treatment until progression, patient refusal, or unacceptable toxicity.~Control group: Patients randomized to the control group of the trial will receive bevacizumab at a dose of 5 mg/kg and placebo (NaCl) every two weeks. Patients will receive treatment until progression, patient refusal, or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin, 25 Mg/mL Intravenous Solution
Description: Experimental group/ Patients randomized to the experimental group of the trial will receive bevacizumab as an IV infusion at a dose of 10 mg/kg, administered in 2 preparations of 5 mg/kg, every 2 weeks. Patients will receive treatment until progression, patient refusal, or unacceptable toxicity.~Control group: Patients randomized to the control group of the trial will receive bevacizumab at a dose of 5 mg/kg and placebo (NaCl) every two weeks. Patients will receive treatment until progression, patient refusal, or unacceptable toxicity.
Study: NCT04890314

Intervention type: OTHER
Intervention: Patient-reported questionnaire
Description: Validated questionnaires administered at baseline, 8 months following treatment, and 12 months following treatment.

Intervention type: OTHER
Intervention: Patient-reported questionnaire
Description: Validated questionnaires administered at baseline, 8 months following treatment, and 12 months following treatment.
Study: NCT06466434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prebiotic Food-Enriched Diet
Description: Given by PO
Study: NCT05014126

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain, Stress and Emotions
Description: 2-hour, zoom-delivered, group intervention focused on teaching patients how pain is processed in their brain and learning about the role of psychosocial factors in their pain conditions.
Study: NCT04890314

Intervention type: OTHER
Intervention: Patient-reported questionnaire
Description: Validated questionnaires administered at baseline, 8 months following treatment, and 12 months following treatment.
Study: NCT05555693

Intervention type: OTHER
Intervention: Collecting clinical data, EGG，Brain Metabolomic Characteristics(with Magnetic Resonance Spectroscopy), blood gas data and blood sample
Description: Collecting clinical data(before induction of anesthesia and first day after surgery), EGG（first day after surgery），Magnetic Resonance Spectroscopy data (before induction of anesthesia and first day after surgery)blood gas data(before induction of anesthesia and first day after surgery) and blood sample （before induction of anesthesia and first day, third day and 7th day after surgery）

Intervention type: OTHER
Intervention: Collecting clinical data, EGG，Brain Metabolomic Characteristics(with Magnetic Resonance Spectroscopy), blood gas data and blood sample
Description: Collecting clinical data(before induction of anesthesia and first day after surgery), EGG（first day after surgery），Magnetic Resonance Spectroscopy data (before induction of anesthesia and first day after surgery)blood gas data(before induction of anesthesia and first day after surgery) and blood sample （before induction of anesthesia and first day, third day and 7th day after surgery）
Study: NCT05663034

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-based treatment for insomnia (MBTI)
Description: A 6-week intervention that uses the principles and practices of mindfulness meditation along with behavioral strategies (stimulus control, sleep restriction therapy) to reduce symptoms of insomnia

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy for insomnia (CBT-I)
Description: Standard of care for adults with chronic insomnia. 6-week program that uses behavioral techniques to decrease psychophysiological arousal and increase sleep propensity to deepen and consolidate sleep.
Study: NCT06004050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delgocitinib
Description: Topical administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delgocitinib
Description: Topical administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: Topical administration
Study: NCT04921501

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD ECG
Description: This experimental procedure is a passive, non-invasive, high-density surface ECG recording using 128 skin electrodes.The electrodes are positioned on strips of 10 electrodes to be prepared with adhesive tape and coated with conductive gel before installation on the patient. The total duration of the acquisition is 10 to 30 minutes.
Study: NCT05265377

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stelo
Description: Use of Stelo exoskeleton in nine rehabilitation sessions
Study: NCT04707352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: All eligible subjects will receive Dapagliflozin 10 mg each day. The study treatment will be provided for the duration of the trial from baseline (Day 1) through last visit (Day 180).
Study: NCT06420128

Intervention type: OTHER
Intervention: Primary care team
Description: Patients whose general practitioner is a member of a primary care team since at least 12 months
Study: NCT04797897

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CORI
Description: unicondylar knee arthroplasty (UKA) treated with CORI

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: unicondylar knee arthroplasty (UKA) treated with conventional approach with conventional manual instrumentation
Study: NCT06033508

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise with whole body vibration device
Description: exercise with whole body vibration device

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise with whole body vibration device
Description: exercise with whole body vibration device

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo exercise
Description: exercise without vibration on land